What is OneOme?
OneOme provides comprehensive, end-to-end pharmacogenomics solutions for the healthcare industry. Co-founded by Mayo Clinic, the company integrates advanced laboratory testing, population-level analytics, and clinical decision support tools. Its offerings aim to reduce healthcare costs and enhance patient outcomes, serving a global clientele from its Minneapolis, MN headquarters. OneOme's platform supports stakeholders from individual patient testing to broad analytics, alongside laboratory software services.
How much funding has OneOme raised?
OneOme has raised a total of $4.3M across 4 funding rounds:
Unspecified
$1M
Debt
$2.1M
Private Equity
$530K
Debt
$611K
Unspecified (2015): $1M, investors not publicly disclosed
Debt (2016): $2.1M, investors not publicly disclosed
Private Equity (2016): $530K, investors not publicly disclosed
Debt (2021): $611K featuring PPP
Key Investors in OneOme
PPP
Public-Private Partnership
What's next for OneOme?
With a major strategic investment and substantial overall capital, OneOme is positioned for significant scaling and further development of its pharmacogenomics platform. The company's enterprise-level funding suggests a focus on expanding its market reach and deepening its integration within healthcare systems. Future initiatives will likely involve enhancing its analytical capabilities and clinical decision support tools to drive broader adoption of precision medicine, potentially exploring new partnerships and technological advancements to solidify its leadership in the pharmacogenomics space.
See full OneOme company page
